Descripción del proyecto
Innovaciones para comprender y prevenir la obesidad infantil
La obesidad en la adolescencia tardía puede tener efectos perjudiciales duraderos, que contribuyen a sufrir obesidad grave, diabetes, enfermedades cardiovasculares, muerte prematura y discapacidad. Sin embargo, el tratamiento de la obesidad durante la juventud puede dar resultados positivos. Dado el aumento de las tasas de obesidad infantil en Europa, es crucial dar prioridad a unas estrategias de prevención y tratamiento eficaces. El equipo del proyecto OBELISK, financiado con fondos europeos, pretende aportar datos sobre las causas de la obesidad y ofrecer medicina de precisión a los niños con obesidad. Introducirá innovaciones en la comprensión de los mecanismos moleculares subyacentes a la interacción de los factores causales que bien permiten o bien impiden la transición a la obesidad durante la infancia. También desarrollará herramientas de predicción temprana. El equipo de OBELISK colaborará con familias, comunidades científicas y médicas, escuelas, municipios e industrias.
Objetivo
Obesity rates in late teens have increased in Europe from 6% in 1980 to 32%, with long-lasting effects on the prevalence of severe obesity, diabetes and cardiovascular disease, premature death and disability. Efficiently fighting adult obesity is difficult but prevention and treatment of obesity have proven to work better at young ages. OBELISK goal is to cut the roots of the pandemic of obesity in Europe targeting children first. OBELISK is focused on elucidating, Predicting, Preventing obesity and bringing Precision medicine for children with obesity. OBELISK medicine is also Participative (4P), leveraging the potential of social innovation through engagement with families, scientific and medical communities, daycare, schools, municipalities, industries to achieve success.
OBELISK objectives are: 1/ to bring breakthroughs in the molecular mechanisms by which causative factors interact to drive (or prevent) the transition from normal weight to obesity during childhood and to develop and exploit for prevention and treatment early predictive proprietary tools; 2/ to identify at least 3 novel childhood obesity genes with the prospect of identifying additional drug targets; 3/ to demonstrate the utility of targeted approaches to prevent childhood obesity; 4/ to bring breakthroughs in childhood obesity treatment including a real-life clinical study of a promising existing drug (GLP1R agonist) to reverse obesity in people with mutations predisposing to early severe obesity; 5/ to exploit the project results and disseminate best practices to prevent and treat childhood obesity, implementing education programs and translating OBELISK clinical results into guidelines and proposals for policy makers to change obesity care; 6/ to facilitate networking and exchanges with other actions and projects in order to optimize knowledge and joint activities.
OBELISK targeted approach should contribute to decrease by 35% the number of children with obesity becoming adults with obesity.
Ámbito científico
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health scienceshealth sciencespersonalized medicine
- medical and health scienceshealth sciencesnutritionobesity
Palabras clave
Programa(s)
Tema(s)
Convocatoria de propuestas
HORIZON-HLTH-2022-STAYHLTH-01-two-stage
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinador
75654 Paris
Francia